439 related articles for article (PubMed ID: 32584416)
1. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
[No Abstract] [Full Text] [Related]
2. Interleukin-6 blockade treatment for COVID-19 associated cytokine release syndrome in a patient with poorly controlled chronic myeloid leukaemia.
Ranger A; Haji R; Kaczmarski R; Danga A
Br J Haematol; 2020 Aug; 190(3):e128-e130. PubMed ID: 32480422
[No Abstract] [Full Text] [Related]
3. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
4. Cytokine Storm Drugs Move from CAR T to COVID-19.
Cancer Discov; 2020 Jul; 10(7):OF8. PubMed ID: 32371479
[TBL] [Abstract][Full Text] [Related]
5. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge.
Carnero Contentti E; Correa J
Mult Scler Relat Disord; 2020 Jun; 41():102097. PubMed ID: 32278860
[No Abstract] [Full Text] [Related]
7. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
8. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications.
Smetana K; Brábek J
In Vivo; 2020 Jun; 34(3 Suppl):1589-1592. PubMed ID: 32503815
[TBL] [Abstract][Full Text] [Related]
9. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
10. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab.
Gautier-Vargas G; Baldacini C; Benotmane I; Keller N; Perrin P; Moulin B; Caillard S
Kidney Int; 2020 Aug; 98(2):508-509. PubMed ID: 32505467
[No Abstract] [Full Text] [Related]
11. On the Alert for Cytokine Storm: Immunopathology in COVID-19.
Henderson LA; Canna SW; Schulert GS; Volpi S; Lee PY; Kernan KF; Caricchio R; Mahmud S; Hazen MM; Halyabar O; Hoyt KJ; Han J; Grom AA; Gattorno M; Ravelli A; De Benedetti F; Behrens EM; Cron RQ; Nigrovic PA
Arthritis Rheumatol; 2020 Jul; 72(7):1059-1063. PubMed ID: 32293098
[TBL] [Abstract][Full Text] [Related]
12. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
Miao Y; Fan L; Li JY
Front Immunol; 2020; 11():1445. PubMed ID: 32612616
[No Abstract] [Full Text] [Related]
13. A plea for the pathogenic role of immune complexes in severe Covid-19.
Vuitton DA; Vuitton L; Seillès E; Galanaud P
Clin Immunol; 2020 Aug; 217():108493. PubMed ID: 32526273
[No Abstract] [Full Text] [Related]
14. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
[TBL] [Abstract][Full Text] [Related]
15. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
Moutsopoulos HM
Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
[No Abstract] [Full Text] [Related]
16. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
17. Defining the Cytokine Storm Syndrome of COVID-19: Role of the Clinical Laboratory.
Jialal I; Devaraj S
Ann Clin Lab Sci; 2020 Sep; 50(5):703-705. PubMed ID: 33067221
[No Abstract] [Full Text] [Related]
18. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.
Abdulrab S; Al-Maweri S; Halboub E
Med Hypotheses; 2020 Oct; 143():109897. PubMed ID: 32505909
[No Abstract] [Full Text] [Related]
19. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
20. Cytokines and COVID-19: friends or foes?
Rokni M; Hamblin MR; Rezaei N
Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]